Skip to main content

Tourette's Disorder

10
Pipeline Programs
2
Companies
8
Clinical Trials
1 recruiting
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
5
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%
+ 3 programs with unclassified modality

On Market (5)

Approved therapies currently available

Otsuka
ABILIFY ASIMTUFIIApproved
aripiprazole
Otsuka
Atypical Antipsychotic [EPC]intramuscular2023
13M Part D
Otsuka
ABILIFYApproved
aripiprazole
Otsuka
Atypical Antipsychotic [EPC]oral2002
12M Part D
Otsuka
MEZOFYApproved
aripiprazole
Otsuka
oral2025
Otsuka
OPIPZAApproved
aripiprazole
Otsuka
Atypical Antipsychotic [EPC]oral2024
Otsuka
ABILIFY MAINTENA KITApproved
aripiprazole
Otsuka
intramuscular2013

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
6 programs
5
1
AripiprazolePhase 3Small Molecule1 trial
AripiprazolePhase 3Small Molecule1 trial
AripiprazolePhase 3Small Molecule1 trial
AripiprazolePhase 3Small Molecule1 trial
AripiprazolePhase 3Small Molecule1 trial
+1 more programs
Active Trials
NCT01795105Completed692Est. May 2015
NCT01727713Completed110Est. Sep 2014
NCT01416441Completed170Est. Mar 2014
+3 more trials
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
Forehead Temperature-Regulating TherapyN/A1 trial
Wearable short wavelength light therapyN/A1 trial
Active Trials
NCT05499741Recruiting25Est. Jan 2026
NCT03508245Completed35Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OtsukaAripiprazole
OtsukaAripiprazole
OtsukaAripiprazole
OtsukaAripiprazole
OtsukaAripiprazole
Angeles TherapeuticsForehead Temperature-Regulating Therapy
Angeles TherapeuticsWearable short wavelength light therapy
OtsukaABF Tourette's Disorder Post Marketing Surveillance Study

Clinical Trials (8)

Total enrollment: 1,383 patients across 8 trials

NCT01727713OtsukaAripiprazole

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Start: Jan 2013Est. completion: Sep 2014110 patients
Phase 3Completed
NCT01727700OtsukaAripiprazole

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Start: Nov 2012Est. completion: Sep 2013133 patients
Phase 3Completed
NCT01416441OtsukaAripiprazole

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Start: Oct 2011Est. completion: Mar 2014170 patients
Phase 3Completed
NCT01418352OtsukaAripiprazole

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Start: Aug 2011Est. completion: Mar 201483 patients
Phase 3Completed
NCT01418339OtsukaAripiprazole

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Start: Jul 2011Est. completion: Nov 2013135 patients
Phase 3Completed
NCT05499741Angeles TherapeuticsForehead Temperature-Regulating Therapy

Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder

Start: Apr 2023Est. completion: Jan 202625 patients
N/ARecruiting
NCT03508245Angeles TherapeuticsWearable short wavelength light therapy

Investigating Circadian Rhythms in Youth With Persistent Tic Disorders

Start: Jan 2018Est. completion: Jun 202335 patients
N/ACompleted
NCT01795105OtsukaABF Tourette's Disorder Post Marketing Surveillance Study

ABF Tourette's Disorder Post Marketing Surveillance Study

Start: Jun 2012Est. completion: May 2015692 patients
N/ACompleted

Related Jobs

Head of Manufacturing Science & Technology (m/w/d)

Viatris (2)Viatris (2)
Troisdorf, North Rhine-Westphalia, Germany
4w ago

Fachlagerist (m/w/d)

Viatris (2)Viatris (2)
Troisdorf, North Rhine-Westphalia, Germany
1mo ago

Laborleiter – Rohstoffe & Packmittel (m/w/d)

Viatris (2)Viatris (2)
Troisdorf, North Rhine-Westphalia, Germany
1mo ago

Medical Representative

Viatris (2)Viatris (2)
Remote
1mo ago

Accounting Manager (m/w/d)

Viatris (2)Viatris (2)
Bad Homburg, Hesse, Germany
1mo ago

Supply Chain Administrator (m/w/d)

Viatris (2)Viatris (2)
Troisdorf, North Rhine-Westphalia, Germany
1mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,383 patients
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.